
Compass Pathways
Compass is a biotechnology company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care.
- Est. revenue
- $20M–$50M
- Total raised
- $771M
- Latest round
- Post-IPO Equity
- Employees
- 313
Funding & revenue at Compass Pathways
How well capitalized the business is — useful context before you scope a fractional engagement or negotiate a rate.
Estimated annual revenue
$20M–$50M
Modeled range, not company-reported
Total capital raised
$771M
25 known investors
Latest round
Post-IPO Equity · $200M
Feb 2026
Publicly traded
CMPS
IPO Sep 2020
Investors
Growth signals
How fast Compass Pathways is adding people, roles, and audience.
Employees
313
Reported band 51-200
LinkedIn followers
46.5K
+26.2% year over year
Headcount change
- MoM
- +5.4%
- +16 people
- QoQ
- +13.8%
- +38 people
- 6mo
- +26.2%
- +65 people
- YoY
- +40.4%
- +90 people
- 2yr
- +17.7%
- +47 people
Team composition
Where Compass Pathways concentrates its people — a read on which function a fractional leader would plug into.
By function
- Healthcare Services4615%
- Research4414%
- Business Development237%
- Legal175%
- Program And Project Management175%
- Sales134%
- Operations134%
- Information Technology134%
By region
- United States194
- United Kingdom99
- England, United Kingdom90
- London Area, United Kingdom62
- Greater London56
- New York City Metropolitan Area49
Inside Compass Pathways
What the business focuses on, where it operates, and how employees rate it.
Categories
Markets
Competitors
Companies in the same market as Compass Pathways.
Compass Pathways in the news
Recent coverage picked up alongside the firmographic refresh.
- COMP360 Psilocybin NDA Submitted to FDA for Treatment-Resistant Depression
Nov 2026
- Compass Pathways stock gains on FDA filing for depression drug
Nov 2026
- COMPASS Pathways files NDA for COMP360 psilocybin in treatment-resistant depression
Nov 2026
- Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
Nov 2026
- Compass Pathways could secure US approval for depression drug by early 2027, Jefferies says
Nov 2026
- NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
Nov 2026
Jobs
1Funding, revenue, headcount, and hiring figures are third-party estimates from public sources and are not confirmed by the company. Last refreshed November 19, 2026.
About this page
This company page is automatically generated based on publicly available job postings. Company information is sourced from publicly available data and may not be complete. If you represent Compass Pathways, you can claim this page to manage and enhance it.